22 / 61
Median 12.6 vs 10.3 mo
1 H. Borghaei: Nivolumab vs docetaxel in patients with advanced NSCLC: CheckMate -017/-057 2-year update and exploratory cytokine profile analyses
Abstract #9025, Poster Board #348, ASCO 2016
Patients (number)
Probability of survival (%)
Time (months)
Lume Lung 1
CheckMate 057: Updated 2-year survival
rates show similar results as LUME-Lung 1